University of Utah, PPDS

Salt Lake City, Utah 84132

1 studies enrolling now · 7 studies all time

What they study most

COVID-19, Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy (DMD), Idiopathic Pulmonary Fibrosis, Mucopolysaccharidosis II, Pompe Disease (Late-onset), Systemic Sclerosis With Lung Involvement

Studies at this site

• A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) — Recruiting now
• A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease — Stopped early
• Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping — Running, not enrolling
• A Study to Investigate Leramistat in Patients With IPF — Withdrawn before enrolling
• An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy — Stopped early
• A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19 — Completed